Retatrutid

Retatrutide (LY3437943) — GLP-1 / GIP / Glucagon Triple Agonist

Retatrutide is a synthetic research peptide developed by Eli Lilly that activates three different metabolic hormone receptors at once: GLP-1 (the same system targeted by semaglutide, the active ingredient in Ozempic and Wegovy), GIP (a gut hormone that regulates insulin, also hit by tirzepatide / Mounjaro), and glucagon (the hormone that tells the body to release stored energy). Most compounds in this class hit one or two of these receptors – retatrutide is the first peptide to hit all three in a single molecule, which is why it is sometimes nicknamed “GLP-3” and is one of the most actively studied peptides in obesity and metabolic research.

Why Triple Agonism Matters

GLP-1 and GIP work mostly on the “intake” side of the energy equation – they reduce appetite, slow digestion, and improve how the body handles sugar. The glucagon receptor adds something different: it works on the “output” side, telling the body to burn stored fat and raise its baseline energy expenditure. By combining both sides in one molecule, researchers can study intake and expenditure together rather than in isolation.

Retatrutide vs Tirzepatide vs Semaglutide

All three peptides come from the same research lineage, but they don’t hit the same receptors. A quick comparison of how they differ at the receptor level:

The practical research difference: tirzepatide added GIP to what semaglutide already did, and retatrutide added glucagon on top of that. Phase 2 trial data published in the New England Journal of Medicine (Jastreboff et al., 2023) reported average weight reductions of about 24% at the highest retatrutide dose over 48 weeks, which is higher than what has been reported in equivalent-length trials of semaglutide or tirzepatide – though direct head-to-head studies are still ongoing.

Forschungsanwendungen

Retatrutide is used in studies examining:

• Body composition changes under sustained caloric restriction
• How triple-agonist protocols compare to single or dual agonists like semaglutide and tirzepatide
• Blood sugar and insulin response in metabolic models
• Fat accumulation in the liver and its reversal (MASLD / NAFLD research)
• Dose-response curves during gradual dose escalation
• Cardiovascular and metabolic markers under extended exposure

Technische Daten

Rekonstitution

Retatrutide arrives as a freeze-dried powder and has to be mixed with bacteriostatic water before use. The math is simple:

Gesamtmenge in mg im Fläschchen ÷ hinzugefügte Wassermenge in ml = mg pro ml

Example: a 10mg vial + 2mL of bacteriostatic water = 5mg per mL.

Nach der Zubereitung bei 2–8 °C lagern und innerhalb von 28–30 Tagen verbrauchen.

Anmerkungen zum Protokoll

The following values are reference points extracted from published clinical and preclinical retatrutide studies – not instructions. Because retatrutide is active at three receptors, gradual dose escalation is standard throughout the literature, which lets researchers characterize the dose-response curve and lets subjects adapt at each step.

• Starting doses reported in the literature: 0.5-1mg per administration
• Escalation pattern observed: 0.5-1mg increase every 1-2 weeks
• Administration frequency in published trials: Weekly or every other week
• Study durations reported: 8-12 weeks for body composition endpoints; 48 weeks in the published Phase 2 trial

Common Questions About Retatrutide Research

Is retatrutide the same as Ozempic?

No. Ozempic is a brand name for semaglutide, which activates one receptor (GLP-1). Retatrutide activates three receptors (GLP-1, GIP, and glucagon) in a single molecule. They come from different manufacturers – semaglutide from Novo Nordisk, retatrutide from Eli Lilly – and behave differently in metabolic research.

What is the difference between retatrutide and tirzepatide?

Tirzepatide (the active ingredient in Mounjaro and Zepbound) activates GLP-1 and GIP. Retatrutide activates those same two receptors plus glucagon. The added glucagon signaling is the key mechanistic difference and is what researchers point to when explaining retatrutide’s stronger effect on body fat and liver fat markers in published trials.

Why is retatrutide sometimes called GLP-3?

“GLP-3” is an informal nickname used in the research community because retatrutide is the third-generation development in the GLP-1 / GLP-1+GIP / GLP-1+GIP+glucagon progression. It is not an official receptor name or a separate molecule – the technical label is “triple agonist” and the compound’s development code is LY3437943.

Is retatrutide FDA approved?

No. As of the most recent public data, retatrutide is still in Phase 3 clinical trials. It is not approved by the FDA for any use. Every vial WWP ships is labeled and sold strictly for laboratory and research use only, not for human consumption.

How is retatrutide stored?

Ungeöffnete Fläschchen werden bei 2–8 °C (Kühlschranktemperatur) gelagert und sind mindestens 12 Monate lang haltbar. Nach der Rekonstitution mit bakteriostatischem Wasser wird die Lösung bei 2–8 °C aufbewahrt und innerhalb von 28–30 Tagen verbraucht.

Reinheitsgarantie

Jede Charge weist eine Reinheit von ≥99 % auf. Senden Sie uns ein Analysezertifikat einer unabhängigen Prüfstelle, und wir stellen Ihnen unabhängig vom Ergebnis eine Gutschrift aus.